Viking Therapeutics, Inc.
24.40USD
-1.4300 (-5.54%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on VKTX.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$1.06▲ | -$1.1 | 9 | 6 |
| Next quarter | -$1.09▼ | -$1.07 | 7 | 9 |
| Current year | -$4.59▲ | -$4.72 | 9 | 7 |
| Next year | -$4.34▲ | -$4.57 | 1 | 0 |
Beat in 1 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$1.21 | -$1.1 | +0.11 (+8.9%) |
| 2026-03-31 | -$0.91 | -$1.37 | -0.46 (-50.5%) |
| 2025-12-31 | -$0.9 | -$1.38 | -0.48 (-53.1%) |
| 2025-09-30 | -$0.67 | -$0.81 | -0.14 (-20.1%) |
132 ratings from 26 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| Canaccord Genuity | Maintained | Buy | $114 $106 | Oct 20, 2026 |
| UBS | Initiated | Buy | $94 | Oct 15, 2026 |
| Truist Securities | Maintained | Buy | $87 $85 | Oct 7, 2026 |
| Truist Securities | Maintained | Buy | $83 $87 | Sep 23, 2026 |
| JP Morgan | Maintained | Overweight | $75 $65 | Aug 11, 2026 |
| Canaccord Genuity | Maintained | Buy | $107 $114 | Jul 30, 2026 |
| Lake Street | Initiated | Buy | $89 | May 28, 2026 |
| BTIG | Reiterated | Buy | $125 | May 1, 2026 |
| Cantor Fitzgerald | Maintained | Overweight | $105 $100 | Apr 30, 2026 |
| HC Wainwright & Co. | Reiterated | Buy | $102 | Mar 23, 2026 |
| Canaccord Genuity | Maintained | Buy | $106 $107 | Nov 12, 2025 |
| Canaccord Genuity | Initiated | Buy | $106 | Oct 29, 2025 |
| JP Morgan | Maintained | Overweight | $80 $75 | Oct 24, 2025 |
| Morgan Stanley | Maintained | Overweight | $98 $102 | Oct 23, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $102 | Sep 29, 2025 |
| BTIG | Reiterated | Buy | $125 | Sep 22, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $102 | Aug 19, 2025 |
| Raymond James | Maintained | Strong Buy | $125 $122 | Jul 24, 2025 |
| Citigroup | Maintained | Neutral | $31 $38 | Jul 24, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $102 | Jun 25, 2025 |
| Cantor Fitzgerald | Initiated | Overweight | $104 | Apr 28, 2025 |
| Truist Securities | Reiterated | Buy | $95 $75 | Apr 28, 2025 |
| Morgan Stanley | Maintained | Overweight | $105 $102 | Apr 24, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $102 | Apr 24, 2025 |
| HC Wainwright & Co. | Reiterated | Buy | $102 | Apr 17, 2025 |
52 filings from 10 insiders · 4 buy / 3 sell over 6m
Officers and directors of VKTX, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| KELLY-GEMMELL DOROTHY ELIZABETHDirector | Grant | 6.3k | — | — | Jul 31, 2026 |
| ZANTE GREGORY SChief Financial Officer | Sell | 21.2k | $33.47 | $710k | Jul 29, 2026 |
| MANCINI MARIANNAChief Operating Officer | Sell | 18.2k | $33.47 | $610k | Jul 29, 2026 |
| LIAN BRIANChief Executive Officer | Sell | 148.5k | $33.32 | $4.95M | Jul 29, 2026 |
| MANCINI MARIANNAChief Operating Officer | Grant | 31.7k | — | — | Jul 28, 2026 |
| LIAN BRIANChief Executive Officer | Grant | 221.7k | — | — | Jul 28, 2026 |
| ZANTE GREGORY SChief Financial Officer | Grant | 31.7k | — | — | Jul 28, 2026 |
| AUBUCHON NEIL WILLIAMOfficer | Buy | 4.5k | $33.50 | $150k | Mar 10, 2026 |
| ZANTE GREGORY SChief Financial Officer | Sell | 57.7k | $32.09 | $1.90M | Jan 5, 2026 |
| MANCINI MARIANNAChief Operating Officer | Sell | 57.7k | $32.29 | $1.90M | Jan 5, 2026 |
| LIAN BRIANChief Executive Officer | Sell | 233.4k | $32.29 | $7.69M | Jan 5, 2026 |
| FOEHR MATTHEW WDirector | Exercise | 16.0k | $3.33 | $53k | Jan 2, 2026 |
| FOEHR MATTHEW WDirector | Sell | 16.0k | $35.11 | $562k | Jan 2, 2026 |
| MANCINI MARIANNAChief Operating Officer | Grant | 73.0k | — | — | Jan 2, 2026 |
| ROUAN SARAH KATHRYNDirector | Grant | 3.1k | — | — | Jan 2, 2026 |
| LIAN BRIANChief Executive Officer | Grant | 302.5k | — | — | Jan 2, 2026 |
| MACARTNEY LAWSONDirector | Grant | 3.1k | — | — | Jan 2, 2026 |
| ROWLAND CHARLES A JRDirector | Grant | 3.1k | — | — | Jan 2, 2026 |
| ZANTE GREGORY SChief Financial Officer | Grant | 73.0k | — | — | Jan 2, 2026 |
| SINGLETON J MATTHEWDirector | Grant | 3.1k | — | — | Jan 2, 2026 |
No analyst notes on VKTX yet.
Members whose judged calls on VKTX have played out most reliably.
No settled calls on VKTX yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice
Analyst Ratings
19 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 5 | 14 | 2 | 0 | 0 | Buy1.86 |
| 1 mo ago | 5 | 13 | 2 | 0 | 0 | Buy1.85 |
| 2 mo ago | 5 | 13 | 2 | 0 | 0 | Buy1.85 |
| 3 mo ago | 5 | 13 | 2 | 0 | 0 | Buy1.85 |